Margin operasi Zhengye Corp (ZYBT)

Logo korporat perusahaan Zhengye Corp (ZYBT)

Zhengye Biotechnology (ZYBT) is actively developing its pipeline of biological products to combat zoonotic viruses. The operating income margin demonstrates the business's sensitivity to costs, where -59.20 captures the current state of the parameter. The company's eco-friendly approach reduces the use of antibiotics in livestock farming. Stability is ensured by strict adherence to biosafety protocols and the engagement of specialized immunologists to create vaccines.

Zhengye Biotechnology Co., Ltd. (ZYBT): Rentabilitas dodolan miturut bathi operasi saka 08.01.2025 nganti 20.11.2026

Rincian metrik komprehensif lan analitis jlzybio.com (ZYBT)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:Jilin Zhengye Biotechnology, ZYBT
Barang utama Zhengye Biotechnology

For Zhengye Biotechnology (ZYBT), which specializes in veterinary vaccines, the operating margin determines the production efficiency of livestock pharmaceuticals. This metric is calculated as the ratio of operating profit to total revenue, excluding the impact of taxes and debt service. The recorded operating margin demonstrates the business's ability to generate cash flow from core sales. A compression of this indicator signals rising raw material costs, while a stable level confirms the company's high competitiveness in the Asian market.